Roflumilast, a Type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis

• Main Authors: Maiga, M.C, Ahidjo, B.A, Maiga, M, Bishai, W.R
• Other Authors: MICROBIOLOGY AND IMMUNOLOGY
• Format: Article
• Published: American Society for Microbiology 2020
• Subjects: gamma interferon; interleukin 1beta; isoniazid; roflumilast; tumor necrosis factor alpha; aminopyridine derivative; benzamide derivative; cyclopropane derivative; phosphodiesterase IV inhibitor; tuberculostatic agent; tumor necrosis factor; animal model; antibacterial activity; Article; bacterial clearance; chronic obstructive lung disease; controlled study; cytokine production; female; food and drug administration; median survival time; mortality; mouse; nonhuman; priority journal; tissue distribution; treatment outcome; tuberculosis; animal; Bagg albino mouse; biosynthesis; disease model; drug effects; growth, development and aging; immunology; lung; microbiology; Mycobacterium tuberculosis; survival analysis; Tuberculosis, Pulmonary; Aminopyridines; Animals; Antitubercular Agents; Benzamides; Cyclopropanes; Disease Models, Animal; Female; Interferon-gamma; Interleukin-1beta; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Phosphodiesterase 4 Inhibitors; Survival Analysis; Tumor Necrosis Factor-alpha
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179634
• Institution: National University of Singapore

10.1128/AAC.02145-15